...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies
【24h】

Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies

机译:修订的参考液体肉汤微稀释法测试替拉万星:对MIC结果的影响以及与其他测试方法的相关性

获取原文
获取原文并翻译 | 示例
           

摘要

The reference broth microdilution (BMD) antimicrobial susceptibility testing method for telavancin was revised to include dimethyl sulfoxide (DMSO) as a solvent and diluent for frozen-form panel preparation, following the CLSI recommendations for water-insoluble agents. Polysorbate 80 (P-80) was also added to the test medium to minimize proven drug losses associated with binding to plastic surfaces. Four hundred sixty-two Gram-positive isolates, including a challenge set of organisms with reduced susceptibilities to comparator agents, were selected and tested using the revised method for telavancin, and the MIC results were compared with those tested by the previously established method and several Sensititre dry-form BMD panel formulations. The revised method provided MIC results 2- to 8-fold lower than the previous method when tested against staphylococci and enterococci, resulting in MIC50 values of 0.03 to 0.06 μg/ml for staphylococci and 0.03 and 0.12 μg/ml for Enterococcus faecium and Enterococcus faecalis, respectively. Less-significant MIC decreases (1 to 2 log2 dilution steps) were observed when testing streptococci in broth supplemented with blood, which showed similar MIC50 values for both methods. However, Streptococcus pneumoniae had MIC50 results of 0.008 and 0.03 μg/ml when tested by the revised and previous methods, respectively. Highest essential agreement rates (≥94.0%) were noted for one candidate dry-form panel formulation compared to the revised test. The revised BMD method provides lower MIC results for telavancin, especially when tested against staphylococci and enterococci. This is secondary to the use of DMSO for panel production and the presence of P-80, which ensure the proper telavancin testing concentration and result in a more accurate MIC determination. Moreover, earlier studies where the previous method was applied underestimated the in vitro drug potency.
机译:遵循CLSI对水不溶性试剂的建议,对特拉万星的参考肉汤微稀释(BMD)抗菌药敏试验方法进行了修订,包括二甲亚砜(DMSO)作为溶剂和稀释剂,用于冷冻形式的面板制备。还向测试介质中添加了聚山梨酯80(P-80),以最大程度减少与塑料表面粘合相关的可靠药物损失。使用改良的特拉万星方法,选择并测试了462株革兰氏阳性菌株,包括对比较剂敏感性降低的挑战性微生物,并将MIC结果与通过先前建立的方法进行了比较敏感型干式BMD面板配方。修订后的方法在对葡萄球菌和肠球菌进行测试时,MIC结果比以前的方法低2至8倍,导致葡萄球菌的MIC50值为0.03至0.06μg/ ml,粪肠球菌和粪肠球菌的MIC50值为0.03和0.12μg/ ml , 分别。在添加血液的肉汤中检测链球菌时,观察到的MIC降低幅度较小(1至2 log2稀释步骤),这两种方法的MIC50值均相似。但是,通过修订方法和以前的方法进行测试时,肺炎链球菌的MIC50结果分别为0.008和0.03μg/ ml。与修订后的测试相比,一种候选干形式面板配方的最高基本符合率(≥94.0%)被注意到。修订后的BMD方法对特拉万星的MIC结果较低,尤其是针对葡萄球菌和肠球菌进行测试时。这是使用DMSO进行面板生产以及P-80的存在的次要条件,这确保了适当的特拉万星测试浓度并导致更准确的MIC测定。此外,采用先前方法的较早研究低估了体外药物的效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号